Emotional Incontinence or Major Depression After TBI: One Drug or Two
A young man four weeks post-TBI has both mood-incongruent crying spells and a genuine major depressive episode — two distinct problems that could call for one drug, two drugs, or a slower diagnosis.
D.M., a 27-year-old man, was six weeks from his wedding when the motorcycle accident happened — a detail his fiancée mentions almost immediately, since the date is still sitting on their refrigerator calendar and neither of them has taken it down. He sustained a moderate traumatic brain injury with frontal and temporal contusions, was intubated briefly at the scene, and spent eleven days in the hospital before returning home a little over two weeks ago. His fiancée describes two things she can't reconcile: several times a day he breaks into sudden crying, sometimes mid- sentence, that stops almost as fast as it started and that he himself describes as feeling "disconnected" from — "I wasn't even sad, I just started crying" — and, separately, a real, sustained change in how he seems most of the time: flat, uninterested in his guitar for the first time in a decade, sleeping ten hours and still exhausted, telling her twice this week that he feels like a burden.
These are not the same problem, and treating them as one risks under-treating both. Pseudobulbar affect — emotional lability disconnected from underlying mood, stereotyped, and often more embarrassing than genuinely distressing to the patient in the moment — is well described after traumatic brain injury, arising from disrupted corticobulbar pathways rather than from mood itself; the CNS-LS he completed today scores 24, solidly in the clinically significant range. But his fiancée's second description — sustained low mood, anhedonia specifically toward something he loved, hypersomnia, and a directly stated sense of being a burden — meets full criteria for a major depressive episode on its own, independent of whatever is producing the crying spells; his PHQ-9 today is 19. The two problems arrive with opposite evidentiary situations. Dextromethorphan-quinidine is approved for pseudobulbar affect whatever the underlying cause, and the open-label PRISM II cohort (Hammond et al., 2016) included TBI patients. Sertraline's position is the reverse: the study usually cited for it after brain injury (Fann et al., 2000) enrolled fifteen patients with mild TBI three to twenty-four months out, open-label, and the randomized trial that followed found it no better than placebo. At four weeks from a moderate injury with contusions he sits outside both populations. Four weeks post-injury is also, on its own, a genuinely ambiguous window: some post-TBI mood and affect symptoms evolve substantially over the first months as the injury settles, which argues for real caution before locking in a long-term diagnosis this early — but a PHQ-9 of 19 with an explicit burden statement is not a symptom the team is willing to simply wait out.
Outpatient neuro-rehabilitation follow-up, week four
The lability is the most functionally disruptive symptom right now, and it has the fastest, most specific treatment. I want to correct one thing before we go further, because it changes the shape of this: dextromethorphan-quinidine is not off-label here. Its indication is pseudobulbar affect, full stop — the label makes the point explicitly that PBA arises secondary to a range of otherwise unrelated neurologic conditions. What was studied in ALS and MS (Pioro et al., Annals of Neurology, 2010) is the efficacy, not the indication, and PRISM II (Hammond et al., 2016) went on to report open-label effectiveness in a TBI cohort specifically. It can produce meaningful improvement within days rather than the weeks an antidepressant needs to reach full mood effect. His crying spells are also the symptom his fiancée describes as hardest to be around day to day — treating the lability first buys him, and her, real relief while the mood question gets worked through more carefully.
I'm not suggesting the depression can wait indefinitely — a PHQ-9 of 19 with a burden statement needs a plan today, not eventually. I'm suggesting the fastest-acting, best-targeted intervention for the symptom that's clearly present goes first.
I'd start an SSRI today instead, and not as a second step after the lability drug — but I'm not going to overstate what's behind that. The study people reach for is Fann and colleagues, 2000, and it is an open-label series of fifteen patients with mild TBI, with a placebo run-in rather than a placebo arm. When the same group ran the actual randomized trial (Journal of Head Trauma Rehabilitation, 2017, sixty-two patients), sertraline was not superior to placebo on depression severity, response, or remission, and the pooled meta-analyses since have come out the same way. So I'm arguing from standard of care, not from a positive trial.
That is a weaker argument than I'd like and still the right one. Those trials are small, they are run against a placebo response that is large in this population, and null is not the same as negative — none of them showed harm. Set against that is a young man with a PHQ-9 of 19 who has twice this week told his fiancée he feels like a burden. Starting dextromethorphan-quinidine alone treats the more visible symptom while leaving that on a timeline of "we'll get to it."
And the speed argument cuts against dextromethorphan-quinidine as much as for it. It does nothing for his mood — conceding the point, it is the better-evidenced drug for the symptom it treats, and I'd rather concede that than pretend otherwise. But if we're genuinely worried about how fast he needs relief, the fast relief on offer is for the problem that isn't the dangerous one.
One TBI-specific point worth naming directly: I would not reach for bupropion here even though it's a reasonable first-line antidepressant generally and sometimes preferred for post-TBI apathy specifically — it meaningfully lowers seizure threshold, and four weeks post-contusion, with no settled long-term seizure risk yet established, is exactly the wrong time to add a pro-convulsant antidepressant. Sertraline carries a comparatively low seizure-risk profile among antidepressants.
I'd push back gently on treating this as a clean two-drugs-versus-one-drug question, without disputing that something needs to start today. Four weeks post-TBI is genuinely early — a real share of post-injury mood and affect symptoms shift substantially over the first three months as the injury settles, and locking in a long-term major-depressive-episode framework this early risks over-treating symptoms that were always going to evolve on their own timeline. That's not a reason to withhold anything from a PHQ-9 of 19 with burden ideation — it's a reason to reassess deliberately rather than assume today's picture is his stable baseline.
Practically, that argues for sertraline now — not because it treats both problems, which I don't think the evidence supports (Burns and colleagues showed sertraline helping lability after stroke, in fourteen patients, and nobody has replicated that after TBI), but because it treats the one that can get worse while we watch. If his lability is untouched at four weeks, we will know that, and we can act on it then with a drug that is on-label for it. I'd add a structured CNS-LS and PHQ-9 recheck at four weeks, not just an open-ended "follow up," specifically because this early window is exactly where the diagnostic picture is most likely to still be moving.
Agreed: sertraline started today for the depressive episode, on standard of care rather than on any claim that the TBI-specific randomized evidence supports it — all three voices accepted that the evidence is null and that null against a large placebo response is not a reason to leave a PHQ-9 of 19 with burden ideation untreated. Also agreed that this treats one of his two problems, not both. Bupropion explicitly avoided given his seizure-threshold exposure this early post-injury. A structured CNS-LS and PHQ-9 recheck at four weeks rather than an open-ended follow-up.
Not agreed: whether deferring dextromethorphan-quinidine was right, now that the case for it is the stronger of the two on its own indication. The Neurologist accepted the sequencing but records that the better-evidenced, on-label drug is the one being made to wait, and would add it at four weeks if the spells persist. The Psychiatrist would rather extend sertraline's trial first, concerned that starting a second agent before the first has had a fair run makes it hard to attribute any improvement. The Physiatrist would let the four-week CNS-LS decide it rather than either instinct. Left as a decision for that visit rather than pre-committed today.